U.S. markets open in 6 hours 18 minutes

ORIC Pharmaceuticals, Inc. (ORIC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.94-0.50 (-2.71%)
At close: 4:00PM EDT

ORIC Pharmaceuticals, Inc.

240 East Grand Avenue
2nd Floor
South San Francisco, CA 94080
United States
650 388 5600
http://www.oricpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees66

Key Executives

NameTitlePayExercisedYear Born
Dr. Jacob M. Chacko M.B.A., M.D.Pres, CEO & Director790.96kN/A1979
Mr. Dominic G. Piscitelli CPA, M.B.A., CPAChief Financial Officer568.84kN/A1975
Dr. Pratik S. MultaniChief Medical Officer622.29kN/A1967
Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1959
Dr. Scott W. LoweCo-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Dr. Lori Friedman Ph.D.Chief Scientific OfficerN/AN/A1964
Dr. Christian V. Kuhlen J.D., M.D., Esq.Gen. CounselN/AN/A1973
Ms. Kelly RauberVP of HRN/AN/AN/A
Dr. Edna Chow ManevalSr. VP of Clinical Devel.N/AN/A1960
Mr. Matthew PanuwatChief Bus. OfficerN/AN/A1977
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Astellas Pharma, Inc.; Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Corporate Governance

ORIC Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.